Navigation Links
Cyberonics to Present at Citi 2012 Global Health Care Conference
Date:2/10/2012

HOUSTON, Feb. 10, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the Citi 2012 Global Health Care Conference on Monday, February 27, 2012, in New York.

Greg Browne, Senior Vice President and Chief Financial Officer, will speak at 11:00 AM Eastern Time.  A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on February 27, 2012.    

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.

 

Contact Information

Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main:  (281) 228-7262
Fax:  (281) 218-9332
ir@cyberonics.com

 


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy
2. Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems
3. Cyberonics Announces Resignation of James A. Reinstein, Senior Vice President & Chief Commercial Officer
4. Cyberonics Announces Investment in ImThera Medical
5. Cyberonics to Participate in 2011 UBS Global Life Sciences Conference
6. Cyberonics Reports Fiscal 2012 First Quarter Results
7. Cyberonics to Report Fiscal Year 2012 First Quarter Results and Host Conference Call on August 25, 2011
8. Cyberonics Reports Record Fiscal 2011 Results and Provides Fiscal 2012 Guidance
9. Cyberonics to Participate in 2011 Jefferies Global Healthcare Conference
10. Cyberonics Reports Strong Fiscal 2011 Third Quarter Results and Increases Guidance
11. Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 ... reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the ... which leads to an increase in blood flow and oxygen supply,to ...
... Joint Venture Between Bristol-Myers Squibb, Company ... in HIV Treatment -, PRINCETON, N.J. and ... Company (NYSE: BMY ) and Gilead Sciences, ... Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir ...
Other Medicine Technology:New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...
(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...
(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...
Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Cleft lip/palate cause much more than cosmetic problems 2
... pain continues to impose a huge burden on industrialized ... work absence. Annual costs related to back pain in ... $100 billion per year. , But a systematic review ... the February issue of The Spine Journal ...
... The National Medical Association (NMA) congratulates the President ... voices were heard in today,s forum. The NMA ... Congress, the consumer advocacy community, and other stakeholders, to ... meaningful legislation that the President can sign before the ...
... of adding exercise equals that of stopping smoking, experts say, ... exercising when they are 50 can extend their life span ... Their study found that exercising has the same beneficial effect ... , Nonetheless, almost half of middle-age men don,t exercise, the ...
... 2009) With origins dating back over 4,000 years, ... Asian culture, and is increasingly gaining popularity in the ... believed green tea consumption could cure disease and heal ... potential health benefits of drinking green tea, especially in ...
... Grubb & Ellis Healthcare REIT, Inc. today announced ... an aggregate of four medical office buildings located ... in Menomonee Falls, Milwaukee, Richfield and Mequon, the ... gross leaseable area. "This is a sale/leaseback transaction ...
... Dr. Steven St. Peter Named to Proteon Board of ... of the world,s largest life sciences-dedicated venture capital investors, ... a $38 million Series B equity financing of Proteon ... of MPM Capital, has been named to the Proteon ...
Other Medicine News:Health News:Clinical trials' review finds only exercise to prevent low-back problems 2Health News:Men Who Get Active in Midlife Live Longer 2Health News:Men Who Get Active in Midlife Live Longer 3Health News:Go green for healthy teeth and gums 2Health News:Grubb & Ellis Healthcare REIT Acquires 185,000 SF Wisconsin Medical Office Buildings Portfolio 2Health News:Grubb & Ellis Healthcare REIT Acquires 185,000 SF Wisconsin Medical Office Buildings Portfolio 3Health News:MPM Capital Leads Investment in Proteon Therapeutics 2
Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...
Stylet - Infant Stainless Steel, Flexible, Non-Sterile, Latex Free, With stop, Suitable for tubes 2.0 mm I.D. or larger....
... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...
All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....
Medicine Products: